Lucite commemorative marking a research and development joint venture between Massachusetts-based CRISPR, and German drug company Bayer. The collaboration will center on CRISPR’s gene-editing technology, and focus on the treatment of conditions such as congenital heart disease, blood disorders, and blindness.
(6AGP903)